BeiGene Launching Brukinsa Trial In Later-Stage COVID-19 Patients

"Steven Treon, director of the Bing Center for Waldenstrom’s Macroglobulinemia at Boston’s Dana-Farber Cancer Institute, said his institution also had some anecdotal experiences involving six COVID-19 patients with Waldenstrom’s lymphoma who were on Imbruvica. "

https://www.forbes.com/sites/nathanvardi/2020/04/16/beigene-launching-brukinsa-trial-in-later-stage-covid-19-patients/#603c6cd07d4a